Results 71 to 80 of about 14,257 (250)

Calibration and discrimination ability of the Dat'AIDS score in people living with HIV aged 70 years and older from the Dat'AIDS cohort

HIV Medicine, EarlyView.
Abstract Objective The Dat'AIDS score was developed to predict 5‐year mortality risk in people living with HIV aged 60 and older. However, its validity in people living with HIV aged 70 years and older needed confirmation. Methods This was a multicentre prospective cohort study in the Dat'AIDS French cohort.
Abeo Mousse, Clotilde Allavena, Amandine Gagneux‐Brunon, François Raffi, Laurent Hocqueloux, Claire Genet, Madeline Pascard, Damien Jolly, Firouzé Bani‐Sadr, Lukshe Kanagaratnam, Maxime Hentzien, and The Dat'AIDS Study Group, C. Chirouze, C. Drobacheff‐Thiébaut, A. Foltzer, K. Bouiller, L. Hustache‐Mathieu, Q. Lepiller, F. Bozon, O Babre, AS. Brunel, P. Muret, E. Chevalier, C. Jacomet, H. Laurichesse, O. Lesens, M. Vidal, N. Mrozek, C. Aumeran, O. Baud, V. Corbin, E. Goncalvez, A Mirand, A brebion, C Henquell, I. Lamaury, I. Fabre, E. Curlier, R. Ouissa, C. Herrmann‐Storck, B. Tressieres, MC. Receveur, F. Boulard, C. Daniel, C. Clavel, PM. Roger, S. Markowicz, N. Chellum Rungen, D. Merrien, P. Perré, T. Guimard, O. Bollangier, S. Leautez, M. Morrier, L. Laine, D. Boucher, P. Point, L. Cotte, F. Ader, A. Becker, A. Boibieux, C. Brochier, F Brunel‐Dalmas, O. Cannesson, P. Chiarello, C. Chidiac, S. Degroodt, T. Ferry, M. Godinot, J.M. Livrozet, D. Makhloufi, P. Miailhes, T. Perpoint, M. Perry, C. Pouderoux, S. Roux, C. Triffault‐Fillit, F. Valour, C. Charre, V. Icard, J.C. Tardy, M.A. Trabaud, I. Ravaux, A. Ménard, AY. Belkhir, P. Colson, C. Dhiver, A. Madrid, M. Martin‐Degioanni, L. Meddeb, M. Mokhtari, A. Motte, A. Raoux, C. Toméi, H. Tissot‐Dupont, I. Poizot‐Martin, S. Brégigeon, O. Zaegel‐Faucher, V. Obry‐Roguet, H Laroche, M. Orticoni, M.J. Soavi, E. Ressiot, M.J. Ducassou, I. Jaquet, S. Galie, H. Colson, A.S. Ritleng, A. Ivanova, C. Debreux, C. Lions, T Rojas‐Rojas, A. Cabié, S. Abel, J. Bavay, B. Bigeard, O. Cabras, L. Cuzin, R. Dupin de Majoubert, L. Fagour, K. Guitteaud, A. Marquise, F. Najioullah, S. Pierre‐François, J. Pasquier, P. Richard, K. Rome, JM Turmel, C. Varache, N. Atoui, M. Bistoquet, E Delaporte, V. Le Moing, A. Makinson, N. Meftah, C. Merle de Boever, B. Montes, A. Montoya Ferrer, E. Tuaillon, J. Reynes, B. Lefèvre, E. Jeanmaire, S. Hénard, E. Frentiu, A. Charmillon, A. Legoff, N. Tissot, M. André, L. Boyer, MP. Bouillon, M. Delestan, F. Goehringer, S. Bevilacqua, C. Rabaud, T. May, F. Raffi, C. Allavena, E. Billaud, C. Biron, B. Bonnet, S. Bouchez, D. Boutoille, C. Brunet‐Cartier, C. Deschanvres, B.J. Gaborit, M. Grégoire, O. Grossi, T. Jovelin, M. Lefebvre, P. Le Turnier, R. Lecomte, P. Morineau, V. Reliquet, S. Sécher, M. Cavellec, E. Paredes, A. Soria, V. Ferré, E. André‐Garnier, A. Rodallec, P. Pugliese, S. Breaud, C. Ceppi, D. Chirio, E. Cua, P. Dellamonica, E. Demonchy, A. De Monte, J. Durant, C. Etienne, S. Ferrando, R. Garraffo, C. Michelangeli, V. Mondain, A. Naqvi, N. Oran, I. Perbost, M. Carles, C. Klotz, A. Maka, C. Pradier, B. Prouvost‐Keller, K. Risso, V. Rio, E. Rosenthal, I. Touitou, S. Wehrlen‐Pugliese, G. Zouzou, L. Hocqueloux, C.Mille. T. Prazuck, C. Gubavu, A. Sève, G. Béraud, V. Legros, V. Avettand‐Fènoël, A. Cheret, C. Goujard, Y. Quertainmont, E. Teicher, N. Lerolle, S. Jaureguiberry, R. Colarino, O. Deradji, A. Castro, A. Barrail‐Tran, Y. Yazdanpanah, R. Landman, V. Joly, J. Ghosn, C. Rioux, S. Lariven, A. Gervais, FX. Lescure, S. Matheron, F. Louni, Z. Julia, S. Le GAC C. Charpentier, D. Descamps, G. Peytavin, C. Duvivier, C. Aguilar, F. Alby‐Laurent, K. Amazzough, G. Benabdelmoumen, P. Bossi, G. Cessot, C. Charlier, P.H. Consigny, K. Jidar, E. Lafont, F. Lanternier, J. Leporrier, O. Lortholary, C. Louisin, J. Lourenco, P. Parize, B. Pilmis, C. Rouzaud, F. Touam, MA. Valantin, R. Tubiana, R. Agher, S. Seang, L. Schneider, R. PaLich, C. Blanc, C. Katlama, F. Bani‐Sadr, M. Hentzien, A. Brunet, D. Lambert, C. Strady, M. Moutel, M. Petithomme‐Nanrocki, V. Greigert, I. Kmiec, H. Marty, V. Brodard, C. Arvieux, P. Tattevin, M. Revest, F. Souala, M. Baldeyrou, S. Patrat‐Delon, J.M. Chapplain, F. Benezit, M. Dupont, M. Poinot, A. Maillard, C. Pronier, F. Lemaitre, C. Morlat, M. Poisson‐Vannier, T. Jovelin, JP. Sinteff, A. Gagneux‐Brunon, E. Botelho‐Nevers, A. Frésard, V. Ronat, F. Lucht, D. Rey, P. Fischer, M. Partisani, C. Cheneau, C. Mélounou, C. Bernard‐Henry, E. de Mautort, S. Fafi‐Kremer, P. Delobel, M. Alvarez, N. Biezunski, A. Debard, C. Delpierre, G. Gaube, P. Lansalot, L. Lelièvre, M. Marcel, G. Martin‐Blondel, M. Piffaut, L. Porte, K. Saune, O. Robineau, F. Ajana, E. Aïssi, I. Alcaraz, E. Alidjinou, V. Baclet, L. Bocket, A. Boucher, M. Digumber, T. Huleux, B. Lafon‐Desmurs, A. Meybeck, M. Pradier, M. Tetart, P. Thill, N. Viget, M. Valette   +337 more
wiley   +1 more source

Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis

BMC Infectious Diseases, 2019
Background Network meta-analyses (NMAs) provide comparative treatment effects estimates in the absence of head-to-head randomized controlled trials (RCTs). This NMA compared the efficacy and safety of dolutegravir (DTG) with other recommended or commonly
Sonya J. Snedecor, Matthew Radford, David Kratochvil, Richard Grove, Yogesh S. Punekar   +4 more
doaj   +1 more source

Stable and low prevalence of transmitted HIV type 1 drug resistance despite two decades of antiretroviral therapy in Hong Kong [PDF]

, 2010
Transmitted HIV resistance is of both clinical and public health importance. Baseline genotypic resistance testing was performed for HIV-1-infected treatment-naive patients who were newly diagnosed between 2003 and 2007 and attended the government HIV ...
AlvarezBognar, FR, Chan, KCW, Chan, WK, Chen, JHK, Wong, KH, Yam, WC   +5 more
core   +1 more source

The impact of accumulating immune adaptation in circulating strains of HIV‐1

HIV Medicine, EarlyView.
Abstract Background Mutations in human immunodeficiency virus type 1 (HIV‐1) enable the virus to evade recognition and killing by human leucocyte antigen (HLA)‐restricted T cells. These viral adaptations are specific to the HLA type of individuals and are therefore evident as HLA allele‐HIV sequence associations at the population level. Most studies of
Marwah Al‐kaabi, Alison Castley, Pooja Deshpande, Abha Chopra, David Nolan, Simon Mallal, Mina John, Silvana Gaudieri   +7 more
wiley   +1 more source

Prevalence and Correlates of Pre-Treatment HIV Drug Resistance among HIV-Infected Children in Ethiopia

Viruses, 2019
Pediatric human immunodeficiency virus (HIV) care in resource-limited settings remains a major challenge to achieving global HIV treatment and virologic suppression targets, in part because the administration of combination antiretroviral therapies (cART)
Birkneh Tilahun Tadesse, Olivia Tsai, Adugna Chala, Tolossa Eticha Chaka, Temesgen Eromo, Hope R. Lapointe, Bemuluyigza Baraki, Aniqa Shahid, Sintayehu Tadesse, Eyasu Makonnen, Zabrina L. Brumme, Eleni Aklillu, Chanson J. Brumme   +12 more
doaj   +1 more source

Anti-HIV-1 activity of benzothiadiazine dioxide [PDF]

, 2013
Antiviral assays carried out on the potent benzothiadiazine dioxide (BTD) human cytomegalovirus (HCMV) inhibitors have led us to find marginal but selective anti-HIV-1 activity.
Balzarini, Jan, Castro, Ana, De Clercq, Erik, Gil, Carmen, Martínez, Ana, Pannecouque, C., Pérez, Concepción, Witvrouw, M.   +7 more
core   +2 more sources

Real‐world use of second‐generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS‐CO3‐AquiVIH‐NA cohort

HIV Medicine, EarlyView.
Abstract Objectives To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods People living with HIV from the prospective ANRS‐CO3‐
O. Leleux, A. Peyrouny‐Mazeau, A. Perrier, M. Hessamfar, G. Le Moal, D. Neau, L. Alleman, C. Cazanave, E. Lazaro, P. Duffau, A. Riché, Y. Gérard, G. Barrière, S. Reigadas, M.‐A. Vandenhende, F. Bonnet   +15 more
wiley   +1 more source

The Epidemiology of HIV‐1 Resistance to Two‐Drug Regimens in Multicenter Cohort From Poland—A Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aims Concerns about antiretroviral therapy failure are growing among people with HIV receiving two‐drug regimens, as these schemes include fewer active agents, while the prevalence of transmitted resistance in HIV‐1 continues to increase.
Andrzej Załęski, Agnieszka Lembas, Joanna Osińska, Tomasz Dyda, Magdalena Suchacz, Justyna Stempkowska‐Rejek, Justyna Orzechowska, Alicja Wiercińska‐Drapało   +7 more
wiley   +1 more source

Backbone switch to abacavir/lamivudine fixed-dose combination: implications for antiretroviral therapy optimization [PDF]

, 2015
Current guidelines recommend treatment optimization in virologically suppressed patients through switching/ simplification strategies to minimize long-term toxicities and improve adherence. The assessment of inflammation/ coagulation profiles may support
FALASCA, FRANCESCA, FANTAUZZI, Alessandra, Floridia, Marco, MEZZAROMA, Ivano, SPANEDDA, Pierpaolo, TURRIZIANI, Ombretta, VULLO, Vincenzo   +6 more
core  

Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy [PDF]

, 2014
Fixed-dose combination antiretroviral therapy administered as a single-tablet regimen (STR) may improve virologic suppression rates.
Blanco, Jl, Campos-Loza, Ae, Gatell, Jm, Gonzalez-Hernandez, La, Harrigan, R, Marconi, Vc, Miller, Md, Montaner, Jsg, Nguyen, Ml, Paredes, R, Perno, Cf, Santoro, Mm, Shafer, Rw   +12 more
core   +1 more source